<div id="readability-page-1"><div><p>By Colin Kellaher</p><p>   Shares of Protagonist Therapeutics moved higher after The Wall Street Journal reported that Johnson &amp; Johnson is in talks to buy company, citing people familiar with the matter. </p><p>    Protagonist shares were recently up 9.4%, to $73.34. </p><p>    A deal isn't guaranteed, and the details being discussed couldn't be learned, the people said, the Journal reported. </p><p>    Protagonist sports a market capitalization topping $4 billion based on Thursday's closing price of $67.04 for the Newark, Calif., clinical-stage biopharmaceutical company. </p><p>   Write to Colin Kellaher at colin.kellaher@wsj.com </p><p>   (END) Dow Jones Newswires</p><p>10-10-25 1147ET</p></div></div>

強生

Protagonist治療

<p>Protagonist Therapeutics 的股價上漲 9.4%，至 73.34 美元，此前《華爾街日報》報道強生正在洽談收購該公司。根據最近的收盤價 67.04 美元，Protagonist 的市值超過 40 億美元。然而，交易並未得到保證，具體細節仍未披露</p>

Protagonist 治療公司因可能與強生達成交易的報道而股價大漲